Qureight’s AI 3D imaging platform to support Calluna Pharma’s Phase 2 AURORA study of CAL101 in idiopathic pulmonary fibrosis (IPF)
Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered imaging and clinical data curation platform, today announced